Vedolizumab monoclonal antibodody rau ulcerative colitat

English Lub Npe: Vedolizumab
Tus lej lej: 943609-66-3
Molecular Cov Qauv
Molecular hnyav: 0
Einecs tsis muaj
Lwm yam khoom siv: Tshuaj yeeb; Mab 22; Tswj cov khoom; Tshuaj Nplaum Xov Xwm
Cov Mol cov ntaub ntawv,: Mol cov ntaub ntawv
Cov Qauv Txheej Txheem:

VyDozumab Khoom
Kev Cia Cov Neeg Tiv Thaiv: Khw ntawm -80 c
Solubility: yaj nyob hauv dimethyl sulfoxide
Daim Ntawv: Khoom
Xim: Dawb rau off-dawb
 

Monoclonal antibody

Vedozumab (vedolizumab) yog cov tshuaj pleev roj monoclonal tag nrho} Contactin rau cov hnyuv nplaum molecule madcam {2}}.

Nyob rau hauv lub Tsib Hlis 2014, US FDA pom zoo Vedocizumab rau kev kho mob ntawm cov neeg laus uas muaj mob rwj (CD)

Bioactivity

Vedolizumab yog tib neeg monoclonal antibody hom phiaj 4 7} Txawm muaj protein (congle) rau kev mob caj dab

Phiaj Xwm

Lub moo

Hauv kev kawm vitroVedolizumab tsis khi rau feem ntau ntawm cov cim xeeb cd {{t lymphocytes (60%), neurophils, thiab feem ntau monocytes. Qib siab tshaj plaws ntawm Vedolizumab Binding yog rau cov subset (25%) ntawm tib neeg lub cev ntshav nco txog 17 T-Helper lymphocytes. Vedolizumab kuj khi rau EOSinophils ntawm qib siab, thiab mus rau T-Helper Lymphocytes, naive cyerotoxic, naive kindotoxic, nees killer hlwb, thiab bespophils ntawm qis qis; Vedolizumab Binds rau nco cd {8}} t thiab b lymphocytes nrog subnanomolar potency (}}. {}. 4 nm). Vedolizumab xaiv tau inhcosion adhesion ntawm {12}}}}. {}}.}}}.}}}.}}}}}.}}}.}}}.}}}

Hauv Vivo Tshawb Fawb

Blockade of α4β7 receptors on T-lymphocytes has been shown to occur for several weeks after a single dose of vedolizumab. The drug concentration following the infusion has been shown to be dose related with a mean maximum concentration of 12.5 μg/mL in those receiving 0.5 mg/kg of vedolizumab and 52.0 μg/mL in those receiving 2 mg/kg. The serum half-life of these two doses is 9-12 days respectively and saturation of α4β7 receptors on T-lymphocytes is >90% ntawm ob qho 4-6 lub lis piam tom qab Txoj kev lis ntshav. Nyob rau hauv txoj kev noj tshuaj haus cov tshuaj muaj ntau dua, cov tshuaj muaj ntau ntxiv nrog rau kev ua haujlwm ntau ntxiv nrog rau (Hnub Tim 1

Cov Ntaub Ntawv Seev Cev

Cov ntaub ntawv MSDS

Cim npe nrov: vedolizumab monoclonal antibodody rau ulcerative antibodody, Tuam Tshoj Vedolizumab Monoclonal Antibody rau Ulcitative Cov Neeg Muag Khoom